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Abstract (250 words) 52 
Purpose Antipsychotic prescribing patterns remain unclear in Asia. The aims of our study were 53 
to investigate prescribing trends of antipsychotic medication in the general population, children, 54 
and older patients by drug generation (first or second), the prescribing trend in pregnant women, 55 
the probable indication for antipsychotic prescription, and the prescribing trend by dosage form. 56 
Methods This descriptive study identified and included all patients prescribed antipsychotic in 57 
Hong Kong from 2004 to 2014 using the Clinical Data Analysis and Report System. This study 58 
calculated and reported the prevalence of antipsychotic prescribing in patient groups of interest, 59 
the percentage with diagnoses of mental disorders were derived, and the prevalence of 60 
antipsychotic by dosage forms. 61 
Results The study included 10,109,206 prescriptions of any antipsychotics to 256,903 patients. 62 
Over the study period, the prevalence of antipsychotic prescribing increased from 1.06% to 63 
1.54% in the general population, from 0.10% to 0.23% in children (3-17 years old), and from 64 
2.61% to 3.26% in older patients (≥65 years old). The prevalence of second-generation 65 
antipsychotics increased but the prevalence of first-generation antipsychotics did not. Prevalence 66 
of antipsychotic prescribing in pre-pregnancy, pregnancy, and postpartum timeframes varied 67 
from 0.18% to 0.38%. The percentage of incident prescriptions with a diagnosis of psychosis 68 
decreased from 54.1% to 47.5%.  69 
Conclusions Antipsychotics have been increasingly prescribed in the general population, 70 
children, and older patients. There is an increase in second-generation antipsychotic prescribing. 71 
Over half of incident users had a recent diagnosis of a non-psychotic mental disorder in 2014, 72 
suggesting that off-label prescribing of antipsychotics might be common. 73 
1. Introduction 74 
Antipsychotic drugs (APDs) have been commonly prescribed for the management of 75 
schizophrenia, bipolar disorder, and major depressive disorder1. Safety concerns about APDs use 76 
in specific patient groups including older patients, children, and pregnant women, has been 77 
raised in past decades. Increased risk of mortality with the use of first-generation antipsychotics 78 
(FGAs) and second-generation antipsychotics (SGAs) in older patients with dementia has been 79 
reported2-6. SGAs were approved for some indications in children and adolescents recently7. 80 
However, concerns regarding the safety of SGAs use in children (mostly focusing on metabolic 81 
syndrome and cardiovascular effects) have been raised8 9. Although APDs have been 82 
increasingly prescribed during pregnancy, safety evidence is limited10 11. 83 
The prescribing prevalence of APDs in general practice (GP) settings in the United Kingdom 84 
(UK) and Italy have been reported as 1% to 1.6% between 2000 and 201112-16. In Asia, APDs 85 
prescribing was only investigated in patients with psychotic disorders through a survey15-17, and 86 
their use in the general population of patients and in vulnerable patient groups (children, older 87 
patients, and pregnant women) remains unclear. 88 
Concerns with respect to off-label use of APDs have also been reported. APDs, especially SGAs, 89 
have been widely used off-label for the management of mental disorders including but not 90 
limited to anxiety, attention deficit hyperactivity disorder, dementia, and severe agitation in older 91 
adults18 19. From 2007 to 2011 in UK primary care settings, over half of patients prescribed 92 
FGAs had diagnoses of non-psychotic mental disorders, and a similar proportion was reported in 93 
patients receiving SGAs13. Information regarding off-label use of APDs has not been studied in 94 
Asia. 95 
In addition, although there is limited evidence suggesting superior efficacy and safety of APDs 96 
depot injections compared to oral dosage20, depot injections were prescribed for one quarter to 97 
one third of patients with schizophrenia in western countries21. However, we could find no 98 
previous published studies of the utilization of APDs in depot injections or other dosage forms in 99 
an Asian population.  100 
There were four specific objectives of our study to investigate prescribing of APDs in Hong 101 
Kong (HK), namely to determine the following.  102 
1) The prescribing trend over time of APDs in the general patient population, children, and older 103 
patients by drug generation (FGAs/SGAs).  104 
2) The prescribing trend over time of APDs in pre-pregnancy, pregnancy, and postpartum 105 
timeframes.  106 
3) The probable indication of incident APDs prescriptions.  107 
4) The prescribing trend over time of APDs by dosage forms. 108 
 109 
2. Method 110 
2.1. Data source 111 
We retrieved prescription and diagnosis data from the Clinical Data Analysis and Report System 112 
(CDARS), the clinical database developed by the Hospital Authority, HK, which is a statutory 113 
body managing public hospitals, specialist outpatient clinics, and general outpatient clinics. The 114 
Hospital Authority provides a full range of healthcare services, including primary, secondary, 115 
and tertiary services to all HK residents (>7,300,000 population). Since 1995, patient data 116 
including demographic information, diagnosis, payment method, prescription information, 117 
admission/discharge information and laboratory test results have been made available on 118 
CDARS for research and audit purposes22 23. Prescription records are categorised using the 119 
British National Formulary (BNF) classification in CDARS. Diseases are coded using the 120 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) in 121 
CDARS. The validity and accuracy of the CDARS database have been reported in several earlier 122 
studies24-27.  123 
2.2. Antipsychotic drugs 124 
With reference to the BNF, this study included all medications under categories 4.2.1 and 4.2.2 125 
and classified them as either FGAs or SGAs. The APDs not included in the BNF but prescribed 126 
during the study period were classified as either FGAs or SGAs based on chemical structure or 127 
according to registration information (Supplementary table 1). APDs prescriptions were further 128 
categorized according to dosage form (Supplementary table 2).  129 
2.3. Study population 130 
We retrieved all prescription records of APDs from CDARS. Age was defined using mid-year 131 
age, which is age on 1st July in the year of date of prescription and used to group individuals as 132 
children (3-17 years old) and older patients (≥65 years old).  133 
2.4. Prevalence in the general population and by age group and dosage form 134 
The annual prevalence calculation was adapted from Man et al.25; it was defined as the number 135 
of patients prescribed at least one APDs per calendar year divided by the mid-year population of 136 
HK. The number of patients with at least one APDs prescription during the study period of 1st 137 
January 2004 to 31st December 2014 was used as the numerator in the calculation of prevalence. 138 
Population statistics were requested from the Census and Statistics Department, HK. This study 139 
calculated the prevalence for the general patient population, by drug generation (FGAs/SGAs), 140 
age group and dosage form.  141 
2.5. Prevalence in pregnancy 142 
We identified pregnant women with records of delivery episodes from 1st January 2004 to 31st 143 
December 2014 in the CDARS database and calculated prevalence of APDs use by calendar year 144 
for three timeframes: pre-pregnancy (180 days before conception to conception), pregnancy 145 
(from date of conception to date of delivery), and postpartum (from delivery to 180 days after 146 
delivery). Delivery episodes in calendar year 2003 and 2015 were also included to investigate 147 
their postpartum and pre-pregnancy timeframes overlapping with the study period (2004-2014). 148 
This analysis calculated the annual prevalence of APDs by using the number of women 149 
prescribed APDs during pregnancy in the respective timeframe divided by the total number of 150 
women who were recorded as having been in that pregnancy timeframe during the particular 151 
calendar year. Details of the pregnancy timeframes are included in supplementary material. 152 
2.6. Indication analysis 153 
Using the ICD-9-CM, mental illnesses were categorized as organic psychotic conditions (290-154 
294), other psychoses (295-299), neurotic disorders, personality disorders and other 155 
nonpsychotic mental disorders (300-316), and intellectual disabilities (317-319). Since diagnosis 156 
records of chronic mental disorders are more likely to be omitted in non-incident prescriptions, 157 
this analysis only included new users of APDs. As indication information is not available in 158 
CDARS, all mental illnesses diagnosed within 180 days before or after incident prescriptions 159 
(the first prescription during the study period) were retrieved and considered as probable 160 
indications. As such, it is possible that one APDs prescription could have been mapped to 161 
multiple mental illness categories as probable indications. This analysis calculated the 162 
percentages of patients with probable indications by category. Since a APDs prescription can 163 
belong to multiple mental illness categories, the percentage of patients with probable indications 164 
may sums up exceeding 1. 165 
2.7.Statistical analysis 166 
This descriptive study calculated prevalence (%) using the number of patients in the respective 167 
category divided by the total general population, and then multiplied by 100%.  Annual 168 
prevalence of antipsychotic prescribing was calculated and reported with 95% confidence 169 
intervals (95% CI), estimated using Poisson regression. We tested trends in prevalence over time 170 
using the t-test on the change in annual prevalence, with significance level of 0.05. Statistical 171 
power for the trend test was calculated. Considering data included in trend test is limited (11 data 172 
points), some of the analyses might be underpowered to detect the trend. Statistical computing 173 
software R (version 3.1.2, R Core Team) and SAS software (version 9, SAS Institute Inc.) was 174 
used for data manipulation and analysis. Data was analysed by KSJL using R and independently 175 
cross-checked by AWYT and KKCM.  176 
This study protocol was approved by the Institutional Review Board of the University of Hong 177 
Kong/Hospital Authority Hong Kong West Cluster (reference number: UW 15-619). 178 
3. Results 179 
From 2004 to 2014, there were 10,109,206 APDs prescriptions issued to 256,903 patients (Table 180 
1). Haloperidol (20.7%), chlorpromazine (9.5%) and sulpiride (7.6%) were the most frequently 181 
prescribed FGAs in HK over this period, while risperidone (12.1%), quetiapine (11.3%) and 182 
clozapine (7.1%) were the three most commonly prescribed SGAs (Supplementary table 1). 183 
The prevalence of APDs prescribing in the general population increased 45% from 1.06% (2004) 184 
to 1.54% (2014). The prevalence of FGAs prescribing decreased 13% from 0.95% (2004) to 185 
0.83% (2014), while SGAs prescribing increased by 480% from 0.19% (2004) to 0.91% (2014). 186 
The trend test for any APDs and SGAs showed statistically significant results (Figure 1 and 187 
Supplementary table 3). The statistical power of the trend test of FGAs prescribing prevalence in 188 
the general patient population was 0.42.  The statistical power of trend tests in this groups was 189 
less than 0.8, which indicates that the real trend might be undetectable due to lack of statistical 190 
power. Subsequent analyses with statistical power less than 0.8 should be interpreted as 191 
underpowered similarly. 192 
In children, there was an increase in the prevalence of APDs prescribing from 0.10% (2004) to 193 
0.23% (2014) by 2.3 times. The prevalence of FGAs prescribing decreased 57% from 0.07% 194 
(2004) to 0.03% (2014), while the prevalence of SGAs increased from 0.04% (2004) to 0.21% 195 
(2014) by more than 5 times. Changes in the trends of APDs, FGAs, and SGAs prescribing were 196 
statistically significant (Figure 2 and Supplementary table 4). 197 
In older patients, the prevalence of APDs prescribing increased 24% from 2.61% (2004) to 198 
3.23% (2010) and was then stable at 3.26% (2014). The prevalence of FGAs was stable from 199 
2004 to 2010, followed by an 18% decrease from 2.45% (2010) to 2.01% (2014). The prevalence 200 
of SGAs increased from 0.39% (2004) to 1.52% (2014) by about 4 times. FGAs were more 201 
frequently prescribed than SGAs in this age group throughout the study period. The changes in 202 
prescribing trends of any APDs and SGAs were statistically significant (Figure 3 and 203 
Supplementary table 5). Statistical power of the trend test of FGAs prescribing prevalence in 204 
older patients was 0.28. 205 
There were 320,739 delivery episodes from 319,564 pregnant women identified with at least one 206 
pregnancy timeframe during the study period. Among these, 1,749 women were prescribed 207 
APDs during relevant pregnancy timeframes. From 2004 to 2014, 0.18% to 0.32% of women 208 
were prescribed APDs during the pre-pregnancy timeframe, 0.18% to 0.27% during the 209 
pregnancy timeframe, and 0.30% to 0.38% during the postpartum timeframe (Figure 4 and 210 
Supplementary table 6). There were no statistically significant changes in trends in any annual 211 
APDs prescribing in pre-pregnancy, pregnancy, or postpartum timeframes over the study period. 212 
The highest statistical power of the trend tests of the three timeframes was 0.21.  213 
For the indication analysis, 201,371 new APDs users were identified, among which 104,451 had 214 
a diagnosis of a mental disorder identified within the period of 180 days before or after the date 215 
of the incident prescription (51.9%). The percentage of incident prescriptions associated with the 216 
diagnosis of other psychoses decreased from 54.1% (2004) to 47.5% (2014). The percentage of 217 
incident prescriptions for organic psychotic conditions increased from 38.5% (2004) to 46.1% 218 
(2010), then decreased to 40.4% (2014). For neurotic disorders, personality disorders and other 219 
nonpsychotic mental disorders, this percentage increased from 25.4% to 33.9%. The percentage 220 
of incident APDs prescriptions for intellectual disabilities decreased from 2.7% (2004) to 2.0% 221 
(2014) (Table 2). 222 
Results of prescribing trend by dosage forms showed that the majority of APDs were 223 
administered orally as a tablet or capsule. The annual prevalence increased from 1.00% (2004) to 224 
1.45% (2014) by 45%. The prevalence of depot injection prescribing increased from 0.15% 225 
(2004) to 0.18% (2005) by 20% and remained stable through 2005 to 2014. Prescribing 226 
prevalence of immediate injection increased from 0.08% (2004) to 0.12% (2014). The 227 
prevalence remained stable at 0.02% for oral solutions. Statistically significant change was 228 
detected only in the prevalence in the oral tablet/capsule subgroup (Supplementary table 2). The 229 
highest statistical power of the trend tests for oral solutions, immediate injection, and depot 230 
injection prescribing prevalence was 0.48. 231 
 232 
4. Discussion 233 
APDs prescribing is increasing in HK in the general population, children, and older patients. The 234 
prevalent usage and increase are particularly notable in older patients. Although an increase in 235 
SGAs prescribing was found, SGAs prescribing was less prevalent in HK compared to western 236 
countries. During the study period, the percentage of incident prescriptions for organic psychotic 237 
conditions increased, as did the prescriptions for nonpsychotic disorders. Finally, the most 238 
commonly prescribed dosage form, which was oral tablets/capsules, increased over the study 239 
period, while the prevalence of depot injections remained stable. 240 
4.1.Interpretation and comparison with other studies 241 
We found that 1.06% (2004) to 1.54% (2014) of the HK population were prescribed at least one 242 
APDs and that there was a statistically significant change in prevalence. In comparison, the 243 
annual prevalence of APDs prescribing in patients from GP settings in Italy was reported as 244 
having increased from 1.33% (2000) to 1.74% (2005)14. Using a community population sample 245 
from the Clinical Practice Research Datalink database in the UK, the prescribing prevalence of 246 
APDs and medication used for treating mania was reported as 1.0% and 1.4% in males and 247 
females, respectively, in 201012. Information from GP settings shows a similar increase in APDs 248 
prescribing to the data in our study, which provides a comprehensive view of drug prescribing 249 
from outpatient, inpatient, and emergency departments. However, comparison between our 250 
results and data from other sources needs to take full account of the differences of data source in 251 
the groups studied. 252 
Differences in APDs prescribing were found in specific age groups, including children and older 253 
patients, when comparing the results of our study to those from other regions. Results of a survey 254 
study conducted in the US showed that 1.83% of children (0-13 years old) and 3.76% of 255 
adolescents (14-20 years old) who visited a physician between 2005 and 2009 were prescribed 256 
APDs28, which are higher percentages than the results of our study. The prevalence of APDs 257 
prescribing in older adults (65 years old and above) from GP settings was reported as 3.6% in 258 
Italy in 200514. APDs were prescribed to 12.7% and 12.8% of the older population (≥65 years 259 
old) in Taiwan inpatient and outpatient settings in 2004 and 2005, respectively29. Results of our 260 
study showed that 2.70% of older patients were prescribed APDs, which was lower than the 261 
prevalence reported in Italy and Taiwan. These discrepancies of APDs prescribing in specific age 262 
group could be associated with various factors including local practice. Patient care in regions 263 
may vary due to different clinical guidelines followed. Clinical practice guidelines of early onset 264 
psychoses (less than 18 years old) in US and UK recommend SGAs as treatment option30 31, 265 
while HK local guideline for children and adolescents has not yet been developed. 266 
Compared to HK, SGAs were generally more frequently prescribed in other regions. Our study 267 
showed that the SGAs prevalence did not exceed the FGAs prevalence until 2014. With respect 268 
to the proportion of prescriptions in other regions, SGAs represented 82% of overall APDs 269 
prescriptions in 2002 in Canada32 and 84% in 2002 in the US33. Similar to our findings, and in 270 
contrast to the results from North America, SGAs prescribing lagged behind FGAs prescribing in 271 
inpatient settings in other Asian countries and regions including China, HK, Japan, Korea, 272 
Singapore, and Taiwan15 16. However, the prevalence of SGAs prescribing in HK increased, 273 
while FGAs prescribing decreased over the study period, in the general patient population, 274 
children, and older patient groups. The increase in prescribing SGAs and decrease in FGAs were 275 
also reported in Australia from 2000 through 201134. This indicates that the increase in SGAs 276 
largely accounted for the overall increase in APDs prescribing. This increase in the prescribing 277 
of SGAs could be explained by several factors. In the 2000s, SGAs were recommended as first-278 
line treatment for several mental disorders (e.g. schizophrenia and bipolar disorder) in clinical 279 
practice guidelines20 35-38, including HK local guidelines39, because of their better tolerability 280 
profile and perceived superior efficacy compared to FGAs40 41. The better tolerability profile also 281 
may have decreased the likelihood of treatment discontinuation, which would have lengthened 282 
the duration of prescription and therefore may have increased prevalence, as suggested in a 283 
previous study42. Other reasons could be an increase in the approved indications of SGAs, which 284 
are now approved for the treatment of bipolar mania, adolescent schizophrenia, and behavioural 285 
disturbance associated with autism or intellectual disability in children and adolescents7. 286 
With regard to APDs prescribing in pregnancy, it was expected that the prevalence would take 287 
the “U-shape” pattern (statistically significantly higher prevalence in the timeframes of pre-288 
pregnancy and postpartum, compared to the pregnancy timeframe)43. However, this was not the 289 
case in our study. Although no statistically significant change was detected, our study indicates 290 
that APDs prescribing remains common during the pre-pregnancy, pregnancy, and postpartum 291 
timeframes.  292 
We found that 45.9% of APDs incident prescriptions in 2004 were associated with a diagnosis of 293 
non-psychotic mental disorders, and this number further increased to 52.5% in 2014. These 294 
results may suggest that the off-label prescribing of APDs is expanding, since APDs have not 295 
received approval for most of the mental disorders under these two categories, including 296 
dementia, anxiety disorder, and obsessive compulsive disorder. Since “black-box warnings” have 297 
been issued in relation to the increased mortality in older patients with dementia prescribed 298 
APDs, these drugs should be used with caution in older patients. Close monitoring and more 299 
frequent follow-up should be implemented when APDs are prescribed to patients for unapproved 300 
indications, especially in older patients.  301 
Oral capsule/tablet was the most common route of administration of APDs in HK. Audits and 302 
surveys from 1996 to 2009 reported that from a quarter to a third of sampled patients were 303 
prescribed depot injections in the United States, Europe, Australia, and New Zealand21. It is 304 
noteworthy that a survey reported that 36.7% of sampled stable patients with schizophrenia from 305 
HK outpatient clinics in 2005 and 2006 were prescribed APDs depot injections44. As shown in 306 
our results, no statistically significant change was detected in the annual prevalence of APDs 307 
depot injection prescribing. 308 
 309 
4.2. Strength of this study 310 
To our knowledge, this is the first study describing APDs prescribing trends using population-311 
based database in Asia. Apart from providing information on APDs prescribing in the general 312 
patient population and patient groups of interest, this study also provides prescribing data by 313 
dosage form and on the probable indication of incident APDs prescriptions. Although there are 314 
publications on surveys/audits of APDs prescribing/utilization conducted in Asia at local 315 
hospitals or certain regional clinics, we could find no previous publications on population-based 316 
data. In contrast, data used in this study were derived from CDARS, which consists of medical 317 
records from the HK public healthcare sectors, including inpatient, outpatient, and emergency 318 
department prescriptions.  319 
4.3.Limitations of this study  320 
Since the database used in this study was derived from the public healthcare system, 321 
antipsychotic prescriptions in private clinics were not included, implying that the prevalence of 322 
APDs prescribing may have been underestimated. A previous study suggested that public 323 
healthcare institutions were the mainstay of the mental health service in HK45. As APDs are 324 
generally chronic treatment and patients who require long-term follow-up are more likely to use 325 
public healthcare due to the lower costs, the CDARS data in this study are likely to have 326 
captured most of the APDs prescriptions in HK. In cases where the change in trend over time 327 
was not statistically significant, the analyses were underpowered. Results of this study might not 328 
be generalizable to healthcare systems of other countries/regions due to different local practice of 329 
patient care and age distribution in study population.  330 
 331 
5. Conclusion 332 
Our study has confirmed an increasing trend in APDs prescribing to older patients, suggesting 333 
that attention should particularly focus on the safety and tolerability profile of APDs in this age 334 
group. Further evidence to support the effectiveness and safety of off-label utilization of APDs is 335 
required. With the changes in APDs prescribing over time it is important to determine not only 336 
the differences in beneficial effects but also differences in adverse effects, particularly for 337 
serious, rare, and delayed adverse effects, which may only emerge after considerable clinical 338 
experience has been accumulated. Future observational studies using population-based data 339 
could be of great value in this regard. 340 
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  471 
Table 1. Patient Characteristics  
 Patients with APDs (%) 
Sex       
Male 
Female   
                         123,983 (48.3%) 
                         132,920 (51.7%) 
Age (years)     
Median (IQR)                          60 (38) 
        
Children (3 to 17 years old)   6,996 (2.7%) 
Older patients (65 years old and above)          113,935 (44.3%)  
Total patients with APDs 256,903 (100%) 
        
APDs prescriptions (%) 
        
  FGAs                            5,706,118 (56.4%) 
  SGAs                            4,403,088 (43.6%) 
  Total APDs prescriptions                          10,109,206 (100%) 
   
Age: age at first prescription during study period; APDs: antipsychotic drugs;  472 
FGAs: first generation antipsychotics; SGAs: second generation antipsychotics. 473 
  474 
Table 2. Percentage of incident users by indication category from 2004 to 2014 
 475 
          
  Other psychoses Non-psychotic mental disorder Intellectual disabilities 
Organic psychotic 
conditions 
Year  Percentage, % 
2004 54.14 25.36 2.67 38.47 
2005 53.16 26.15 2.35 40.29 
2006 52.18 26.05 2.49 40.89 
2007 52.83 26.59 2.35 41.79 
2008 50.20 25.82 2.00 44.13 
2009 49.00 26.79 2.47 44.41 
2010 47.66 27.56 2.33 46.10 
2011 46.87 29.29 2.50 45.82 
2012 48.01 29.98 2.26 43.55 
2013 47.98 32.63 2.25 42.11 
2014 47.45 33.89 1.95 40.39 
          
Other psychoses (ICD-9-CM 295-299). Nonpsychotic mental disorder (ICD-9-CM 300-316). Intellectual 476 
disabilities (ICD-9-CM 317-319). Organic psychoses conditions (ICD-9-CM 290-294). ICD-9-CM, 477 
International Classification of Diseases, 9th Revision, Clinical Modification. 478 
  479 
 480 
Figure 1. Prevalence of antipsychotic prescribing in the general population by generation with 95% 481 
confidence intervals from 2004 to 2014.  482 
 483 
Figure 2. Prevalence of antipsychotics prescribing in children (3 to 17 years old) by generation with 95% 484 
confidence intervals from 2004 to 2014.  485 
 486 
Figure 3. Prevalence of antipsychotic prescribing in older patients (≥65 years old) by generation with 95% 487 
confidence interval from 2004 to 2014.  488 
 489 
Figure 4. Prevalence of antipsychotic prescribing in pregnant women in pre-pregnancy, pregnancy, and 490 
postpartum timeframes with 95% confidence intervals from 2004 to 2014. 491 
